Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - ondansetron as hydrochloride dihydrate - solution for injection - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:for the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population:for the mangement of chemotherapy-induced nausea and vomiting (cinv) in children aged ≥ 6 months, and for the prevention and treatment of ponv in children aged ≥ 1 month.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.98 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid monohydrate - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.99 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; citric acid monohydrate; sodium citrate dihydrate; hydrochloric acid; sodium chloride - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; water for injections - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium citrate dihydrate; sodium chloride - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - ondansetron hydrochloride dihydrate 9.972mg equivalent to 8 mg ondansetron - film coated tablet - 8 mg - active: ondansetron hydrochloride dihydrate 9.972mg equivalent to 8 mg ondansetron excipient: lactose magnesium stearate microcrystalline cellulose opadry yellow 03k52033 pregelatinised maize starch purified water - indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron tabs pfizer is also indicated for the prevention of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate dihydrate; water for injections - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 2.5 mg/ml (equivalent: ondansetron, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate dihydrate - ondansetron injection is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ondansetron hydrochloride dihydrate 2.5 mg/ml equivalent to ondansetron 2 mg/ml;   - solution for injection - 2 mg/ml - active: ondansetron hydrochloride dihydrate 2.5 mg/ml equivalent to ondansetron 2 mg/ml   excipient: citric acid monohydrate sodium chloride sodium citrate dihydrate water for injection - ondansetron injection is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron injection is also indicated for the prevention and treatment of post-operative nausea and vomiting.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 2 mg in 1 ml - ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. ondansetron injection is approved for patients aged 6 months and older. ondansetron injection is indicated for the prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients in whom nausea and/or vomiting must be avoided postoperatively, ondansetron injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. for patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting postoperatively, ondansetron injection may be given to prevent further episodes. ondansetron injection is approved for patients aged 1 month and older. ondansetron injection is contraindicated for patients know